Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 33 | 2024 | 2283 | 4.240 |
Why?
|
| Heart Transplantation | 23 | 2023 | 855 | 1.830 |
Why?
|
| Heart-Assist Devices | 20 | 2023 | 1021 | 1.650 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 32 | 1.340 |
Why?
|
| Water-Electrolyte Imbalance | 3 | 2023 | 77 | 1.050 |
Why?
|
| Diuretics | 4 | 2022 | 171 | 1.050 |
Why?
|
| Cardiomyopathies | 8 | 2023 | 492 | 0.960 |
Why?
|
| Hospitalization | 7 | 2024 | 1777 | 0.930 |
Why?
|
| Child | 57 | 2024 | 24375 | 0.920 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2022 | 32 | 0.910 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2021 | 136 | 0.890 |
Why?
|
| Shock, Cardiogenic | 3 | 2024 | 192 | 0.840 |
Why?
|
| Heart Defects, Congenital | 7 | 2023 | 1813 | 0.820 |
Why?
|
| Renal Insufficiency | 3 | 2018 | 236 | 0.800 |
Why?
|
| Hyponatremia | 2 | 2023 | 72 | 0.680 |
Why?
|
| Retrospective Studies | 39 | 2024 | 16314 | 0.660 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 25 | 0.610 |
Why?
|
| Creatinine | 2 | 2018 | 390 | 0.600 |
Why?
|
| Infant | 27 | 2023 | 12469 | 0.590 |
Why?
|
| Child, Preschool | 30 | 2023 | 14009 | 0.580 |
Why?
|
| Hospital Mortality | 7 | 2024 | 1021 | 0.580 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2019 | 626 | 0.570 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 503 | 0.560 |
Why?
|
| Cardiotonic Agents | 4 | 2019 | 138 | 0.550 |
Why?
|
| Anemia | 2 | 2018 | 339 | 0.510 |
Why?
|
| Adolescent | 33 | 2023 | 19280 | 0.490 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2019 | 312 | 0.490 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2014 | 365 | 0.480 |
Why?
|
| Mortality | 1 | 2016 | 238 | 0.470 |
Why?
|
| Humans | 68 | 2024 | 124596 | 0.470 |
Why?
|
| Hospitals, Pediatric | 7 | 2018 | 770 | 0.460 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 87 | 0.460 |
Why?
|
| Male | 47 | 2023 | 61192 | 0.440 |
Why?
|
| Female | 45 | 2023 | 66485 | 0.410 |
Why?
|
| Acute Kidney Injury | 5 | 2023 | 636 | 0.390 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2014 | 257 | 0.360 |
Why?
|
| Graft Rejection | 10 | 2023 | 590 | 0.360 |
Why?
|
| Cohort Studies | 12 | 2021 | 4795 | 0.350 |
Why?
|
| Treatment Outcome | 20 | 2023 | 12322 | 0.330 |
Why?
|
| Risk Factors | 12 | 2024 | 10270 | 0.320 |
Why?
|
| Prognosis | 8 | 2023 | 4626 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 728 | 0.320 |
Why?
|
| Acute Disease | 5 | 2023 | 1110 | 0.320 |
Why?
|
| Cardiology | 1 | 2014 | 504 | 0.300 |
Why?
|
| Infant, Newborn | 13 | 2021 | 8190 | 0.300 |
Why?
|
| Young Adult | 10 | 2023 | 9014 | 0.290 |
Why?
|
| Heart Arrest | 2 | 2014 | 351 | 0.290 |
Why?
|
| Time Factors | 9 | 2020 | 6292 | 0.280 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 22 | 0.280 |
Why?
|
| Registries | 5 | 2021 | 1424 | 0.280 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 236 | 0.260 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 224 | 0.260 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 100 | 0.260 |
Why?
|
| Milrinone | 1 | 2006 | 29 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 243 | 0.250 |
Why?
|
| Incidence | 6 | 2018 | 3138 | 0.250 |
Why?
|
| Pediatrics | 2 | 2019 | 1164 | 0.250 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 174 | 0.240 |
Why?
|
| Adult | 12 | 2024 | 29438 | 0.240 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 727 | 0.240 |
Why?
|
| Patient Readmission | 2 | 2020 | 384 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2020 | 3441 | 0.230 |
Why?
|
| Sodium | 2 | 2023 | 295 | 0.230 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 72 | 0.230 |
Why?
|
| Emergency Service, Hospital | 2 | 2009 | 1088 | 0.230 |
Why?
|
| Length of Stay | 4 | 2019 | 1310 | 0.230 |
Why?
|
| Dopamine | 1 | 2006 | 286 | 0.230 |
Why?
|
| Arginine Vasopressin | 1 | 2004 | 28 | 0.220 |
Why?
|
| Kidney Diseases | 1 | 2008 | 480 | 0.220 |
Why?
|
| Heart Rate | 2 | 2023 | 590 | 0.220 |
Why?
|
| Myocarditis | 3 | 2015 | 130 | 0.200 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 2891 | 0.200 |
Why?
|
| Ambulatory Care | 1 | 2006 | 386 | 0.200 |
Why?
|
| Texas | 6 | 2016 | 3583 | 0.200 |
Why?
|
| Hypernatremia | 1 | 2023 | 29 | 0.200 |
Why?
|
| Developmental Disabilities | 1 | 2007 | 712 | 0.200 |
Why?
|
| Chlorides | 1 | 2022 | 106 | 0.200 |
Why?
|
| Critical Illness | 3 | 2023 | 603 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2016 | 1177 | 0.190 |
Why?
|
| Flecainide | 1 | 2002 | 23 | 0.190 |
Why?
|
| Sotalol | 1 | 2002 | 33 | 0.190 |
Why?
|
| Transferrin | 1 | 2021 | 49 | 0.190 |
Why?
|
| Hypotension | 2 | 2022 | 185 | 0.190 |
Why?
|
| Thrombosis | 2 | 2022 | 520 | 0.180 |
Why?
|
| Multivariate Analysis | 5 | 2019 | 1428 | 0.180 |
Why?
|
| Syndrome | 3 | 2009 | 1119 | 0.180 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2002 | 109 | 0.180 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 32 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 223 | 0.170 |
Why?
|
| North America | 1 | 2020 | 240 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 128 | 0.160 |
Why?
|
| Comorbidity | 3 | 2020 | 1529 | 0.160 |
Why?
|
| Patient Admission | 2 | 2014 | 186 | 0.160 |
Why?
|
| Age Factors | 5 | 2020 | 2818 | 0.160 |
Why?
|
| Iron | 1 | 2021 | 267 | 0.160 |
Why?
|
| Postoperative Complications | 6 | 2016 | 3065 | 0.150 |
Why?
|
| Overweight | 1 | 2021 | 363 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 59 | 0.150 |
Why?
|
| Age of Onset | 1 | 2020 | 586 | 0.150 |
Why?
|
| United States | 7 | 2021 | 10887 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2020 | 192 | 0.150 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 528 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2016 | 1115 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 212 | 0.140 |
Why?
|
| Heart Ventricles | 2 | 2019 | 762 | 0.140 |
Why?
|
| Medical Records | 2 | 2016 | 189 | 0.140 |
Why?
|
| American Heart Association | 1 | 2019 | 322 | 0.140 |
Why?
|
| Echocardiography | 2 | 2018 | 1052 | 0.140 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2009 | 155 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 643 | 0.130 |
Why?
|
| Hypertrophy | 1 | 2016 | 102 | 0.120 |
Why?
|
| Hospital Charges | 1 | 2015 | 61 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.120 |
Why?
|
| Patient Discharge | 2 | 2020 | 489 | 0.120 |
Why?
|
| Disease Progression | 3 | 2016 | 2047 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2016 | 303 | 0.120 |
Why?
|
| Cardiac Catheterization | 3 | 2023 | 632 | 0.110 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 33 | 0.110 |
Why?
|
| Heart | 1 | 2019 | 708 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 1947 | 0.110 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 55 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 879 | 0.110 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2014 | 43 | 0.110 |
Why?
|
| Graft Survival | 4 | 2021 | 536 | 0.110 |
Why?
|
| Prevalence | 2 | 2018 | 2445 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 1254 | 0.100 |
Why?
|
| Biomarkers | 2 | 2016 | 3063 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1660 | 0.100 |
Why?
|
| Stroke Volume | 2 | 2006 | 487 | 0.100 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 192 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2015 | 371 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2019 | 212 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1038 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 221 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2019 | 722 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 115 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1268 | 0.100 |
Why?
|
| Candidiasis | 1 | 2013 | 129 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2007 | 971 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1185 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 314 | 0.080 |
Why?
|
| Colloids | 1 | 2009 | 17 | 0.080 |
Why?
|
| Kidney | 2 | 2023 | 1358 | 0.080 |
Why?
|
| Isotonic Solutions | 1 | 2009 | 35 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2008 | 2154 | 0.080 |
Why?
|
| Natriuretic Agents | 1 | 2009 | 33 | 0.080 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 80 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2020 | 6135 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2021 | 1561 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 506 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2011 | 280 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 557 | 0.070 |
Why?
|
| Hemodynamics | 2 | 2022 | 848 | 0.070 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 129 | 0.070 |
Why?
|
| Consanguinity | 1 | 2007 | 116 | 0.070 |
Why?
|
| Cachexia | 1 | 2007 | 47 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1032 | 0.070 |
Why?
|
| Electromyography | 1 | 2007 | 165 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2007 | 53 | 0.070 |
Why?
|
| Patient Selection | 2 | 2010 | 693 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2006 | 27 | 0.070 |
Why?
|
| Systole | 1 | 2006 | 198 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2008 | 222 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 5145 | 0.060 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2005 | 6 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 172 | 0.060 |
Why?
|
| Myocardium | 2 | 2008 | 997 | 0.060 |
Why?
|
| Leukopenia | 1 | 2005 | 44 | 0.060 |
Why?
|
| Tachycardia | 1 | 2005 | 70 | 0.060 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2005 | 72 | 0.060 |
Why?
|
| Survival Rate | 2 | 2021 | 2044 | 0.060 |
Why?
|
| Cardiac Output, Low | 1 | 2005 | 67 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 711 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3281 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 131 | 0.060 |
Why?
|
| Outpatients | 1 | 2006 | 251 | 0.060 |
Why?
|
| Cause of Death | 1 | 2007 | 473 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2006 | 203 | 0.060 |
Why?
|
| Leukocytes | 1 | 2005 | 205 | 0.060 |
Why?
|
| Probability | 2 | 2019 | 320 | 0.060 |
Why?
|
| Biopsy | 2 | 2023 | 1237 | 0.060 |
Why?
|
| Aortic Coarctation | 1 | 2005 | 109 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 121 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2023 | 45 | 0.050 |
Why?
|
| Obesity | 2 | 2021 | 2262 | 0.050 |
Why?
|
| Dilatation | 1 | 2023 | 64 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2005 | 236 | 0.050 |
Why?
|
| Resuscitation | 1 | 2005 | 250 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2005 | 310 | 0.050 |
Why?
|
| Hirudins | 1 | 2022 | 37 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2003 | 167 | 0.050 |
Why?
|
| Infant Welfare | 1 | 2002 | 28 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2021 | 852 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 56 | 0.050 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2002 | 61 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 647 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2023 | 229 | 0.050 |
Why?
|
| Thinness | 1 | 2021 | 70 | 0.050 |
Why?
|
| Hemolysis | 1 | 2021 | 112 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2005 | 537 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1350 | 0.040 |
Why?
|
| Heparin | 1 | 2022 | 226 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 134 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 123 | 0.040 |
Why?
|
| Quality of Life | 2 | 2020 | 1916 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 467 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 1390 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1162 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 779 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 1420 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1689 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 216 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 460 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 755 | 0.040 |
Why?
|
| Public Health | 1 | 2019 | 262 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 589 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1089 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 460 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2019 | 445 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1805 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1882 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3552 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 553 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 2016 | 36 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1533 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 182 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 1496 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 671 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2016 | 350 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2013 | 11 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 228 | 0.030 |
Why?
|
| Phenotype | 1 | 2023 | 4256 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 510 | 0.030 |
Why?
|
| Heart Diseases | 2 | 2008 | 490 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2013 | 70 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2014 | 174 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 1001 | 0.030 |
Why?
|
| Candida | 1 | 2013 | 75 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 481 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 778 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 78 | 0.020 |
Why?
|
| Forecasting | 1 | 2010 | 351 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 109 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2008 | 72 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 130 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 282 | 0.020 |
Why?
|
| Assisted Circulation | 1 | 2007 | 36 | 0.020 |
Why?
|
| Stroke | 1 | 2015 | 984 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 231 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2010 | 675 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 333 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 190 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 256 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 420 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2008 | 191 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 121 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 429 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Papillary Muscles | 1 | 2005 | 19 | 0.020 |
Why?
|
| Warfarin | 1 | 2006 | 119 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 457 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2005 | 104 | 0.010 |
Why?
|
| Aspirin | 1 | 2006 | 223 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 722 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2008 | 1138 | 0.010 |
Why?
|
| Exercise | 1 | 2009 | 813 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2050 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1620 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 247 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 782 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 874 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2007 | 820 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 947 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2285 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 26714 | 0.000 |
Why?
|